Hepatocellular carcinoma (HCC) is one of the most common solid cancers in the world. Its
treatment strategies have evolved significantly over the past few decades but the best …

In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained
virological response (SVR) is very high, but close attention must be paid to the possible …

BACKGROUND A wide range of ablative and non-surgical therapies are available for
treating small hepatocellular carcinoma in patients with very early or early-stage disease …

Background Alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II
(PIVKA-II) are two commonly used biomarkers for detection and prognostic prediction of …

Background Microvascular invasion (MVI) is recognized as a risk factor for early recurrence
of hepatocellular carcinoma (HCC) within the Milan criteria after curative treatment. Methods …

Background Little evidence exists regarding the perioperative and oncologic benefits of
microwave ablation for hepatocellular carcinoma. The aim of this study was to compare the …

Simple Summary The prognosis of hepatocellular carcinoma is mainly driven by the stage of
the tumor and by the overall liver function status. However, survival rates of patients with …

Background The risk of hepatocellular carcinoma (HCC) is reduced but not eliminated after
nucleos (t) ide analogue (NA) therapy in chronic hepatitis B (CHB). We aimed to investigate …

Simple Summary Atezolizumab plus bevacizumab (Atez/Bev) is the first-line treatment for
unresectable advanced hepatocellular carcinoma (HCC). The tumor markers (TMs) for HCC …

Background LYRM4 is necessary to maintain the stability and activity of the human cysteine
desulfurase complex NFS1-LYRM4-ACP. The existing experimental results indicate that …